Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

July 23, 2026

Study Completion Date

July 23, 2026

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

ADI-PEG20

Lenvatinib + ADI-PEG20 combination treatment.

Trial Locations (1)

RECRUITING

Chang Gung Memorial Hospital, Linkou branch, Taoyuan District

All Listed Sponsors

lead

Chang Gung Memorial Hospital

OTHER